TVTX · Travere Therapeutics, Inc. · Earnings Call Transcripts & Audio
Market Cap
$6.24B
Shares
94.26M
Travere Therapeutics, Inc. Earnings Call Transcripts
Quarterly earnings calls for Travere Therapeutics, Inc. (TVTX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼58.8%
$28.07M
−$69.66M
'22 Q3
22-10-27
·
$29.34M
−$65.82M
'22 Q4
23-01-09
▲31.9%
$30.89M
−$86.33M
'23 Q1
23-05-04
▲12.4%
$32.20M
−$85.63M
'23 Q2
23-08-03
▲32.1%
$37.09M
$150.74M
'23 Q3
23-11-07
▲53.6%
$45.06M
−$90.17M
'23 Q4
24-02-15
▲33.9%
$41.37M
−$136.06M
'24 Q1
24-05-06
▲68.1%
$54.12M
−$70.41M
'24 Q2
24-08-01
▲69.6%
$62.90M
−$54.81M
'24 Q3
24-10-31
▲66%
$74.79M
−$60.26M
'24 Q4
25-02-20
▲97.5%
$81.73M
−$41.23M
'25 Q1
25-05-01
▲111.5%
$114.45M
−$12.76M
'25 Q2
25-08-06
▲162.1%
$164.86M
$25.71M
'25 Q3
25-10-30
▲73.4%
$129.69M
$2.73M
'25 Q4
26-02-19
▲55.6%
$127.20M
−$37.10M
'26 Q1
26-05-04
LATEST
▲48.2%
$169.58M
−$34.80M
'26 Q2
26-08-04
Conference
Investor event
2026-08-11
Travere Therapeutics, Inc. (TVTX) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Travere Therapeutics, Inc. (TVTX) Q2 2026 Earnings Call Transcript
Confident tone
Filspari FSGS launch
Filspari in IgA Nephropathy
Q2 commercial / financial performance
Revenue
$169.58M
▲ 48.2% YoY Diluted EPS
$-0.37
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Travere Therapeutics, Inc. (TVTX) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Travere Therapeutics, Inc. (TVTX) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-04
Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
Confident tone
FSGS approval and launch
IgA nephropathy commercial performance
FSGS patient eligibility and sequencing
Revenue
$127.20M
▲ 55.6% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-13
Travere Therapeutics, Inc. (TVTX) April 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-19
Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
Confident tone
FILSPARI commercial performance in IgA nephropathy
Cross-indication synergy between IgAN and FSGS
FSGS regulatory path and PDUFA
Revenue
$129.69M*
▲ 73.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript
Confident tone
FILSPARI commercial growth in IgA nephropathy
FSGS approval opportunity and launch readiness
REMS modification and potential full removal
Revenue
$164.86M
▲ 162.1% YoY Diluted EPS
$0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript
Confident tone
FILSPARI IgAN commercial performance
FSGS sNDA and regulatory progress
Clinical evidence and SPARTAN/PROTECT data
Revenue
$114.45M
▲ 111.5% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript
Confident tone
FILSPARI in IgA Nephropathy
KDIGO Guidelines and Treatment Practice Changes
FILSPARI sNDA for FSGS
Revenue
$81.73M
▲ 97.5% YoY Diluted EPS
$-0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript
Confident tone
FILSPARI commercial momentum in IgAN
Pre-commercial readiness for potential FSGS launch
FSGS expansion opportunity
Revenue
$74.79M*
▲ 66% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Transcript
Confident tone
REMS liver monitoring modification
FILSPARI IgAN launch
KDIGO guidelines / treatment threshold
Revenue
$62.90M
▲ 69.6% YoY Diluted EPS
$-0.70
▼ 135.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Transcript
Confident tone
FILSPARI launch performance and demand growth
sNDA review and anticipated full approval
FSGS and PARASOL regulatory path
Revenue
$54.12M
▲ 68.1% YoY Diluted EPS
$-0.91
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript
Confident tone
FILSPARI U.S. commercial launch
IgAN treatment paradigm shift
Pegtibatinase / HARMONY Phase 3 program
Revenue
$41.37M
▲ 33.9% YoY Diluted EPS
$-1.76
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript
Confident tone
FILSPARI launch momentum in IgAN
Long-term kidney function data (PROTECT 2-year)
sNDA submission for full approval
Revenue
$45.06M
▲ 53.6% YoY Diluted EPS
$-1.18
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Travere Therapeutics, Inc. (TVTX) Q3 2023 Earnings Call Transcript
Revenue
$37.09M
▲ 32.1% YoY Diluted EPS
$1.97
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Travere Therapeutics, Inc. (TVTX) Q2 2023 Earnings Call Transcript
Revenue
$32.20M
▲ 12.4% YoY Diluted EPS
$-1.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Travere Therapeutics, Inc. (TVTX) Q1 2023 Earnings Call Transcript
Revenue
$30.89M
▲ 31.9% YoY Diluted EPS
$-1.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Travere Therapeutics, Inc. (TVTX) Q4 2022 Earnings Call Transcript
Revenue
$29.34M
Diluted EPS
$-1.03
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Travere Therapeutics, Inc. (TVTX) Q3 2022 Earnings Call Transcript
Revenue
$28.07M
▼ 58.8% YoY Diluted EPS
$-1.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Travere Therapeutics, Inc. (TVTX) Q2 2022 Earnings Call Transcript
Revenue
$28.63M
▼ 47.6% YoY Diluted EPS
$-1.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Travere Therapeutics, Inc. (TVTX) Q1 2022 Earnings Call Transcript
Revenue
$23.41M
▼ 50.6% YoY Diluted EPS
$-1.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Travere Therapeutics, Inc. (TVTX) Q4 2021 Earnings Call Transcript
Revenue
$*
▼ 175.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Travere Therapeutics, Inc. (TVTX) Q3 2021 Earnings Call Transcript
Revenue
$68.22M
▲ 33.4% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Travere Therapeutics, Inc. (TVTX) Q2 2021 Earnings Call Transcript
Revenue
$54.62M
▲ 12.8% YoY Diluted EPS
$-0.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Travere Therapeutics, Inc. (TVTX) Q1 2021 Earnings Call Transcript
Revenue
$47.41M
▼ 0.8% YoY Diluted EPS
$-0.96
▼ 4900% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-10
Travere Therapeutics, Inc. (TVTX) Q4 2020 Earnings Call Transcript
Revenue
$50.98M
▲ 9.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Travere Therapeutics, Inc. (TVTX) Q3 2020 Earnings Call Transcript
Revenue
$51.14M
▲ 15.2% YoY Diluted EPS
$-0.44
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Travere Therapeutics, Inc. (TVTX) Q2 2020 Earnings Call Transcript
Revenue
$48.43M
▲ 8.3% YoY Diluted EPS
$-0.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Travere Therapeutics, Inc. (TVTX) Q1 2020 Earnings Call Transcript
Revenue
$47.77M
▲ 20.7% YoY Diluted EPS
$0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–30 of 30 earnings calls
Key facts
CIK
1438533
CUSIP
89422G107
13F (30d)
105 filings
104 filers
Visit website
Investor relations